Moderna (MRNA) stock
Last close $199.33 on 2026-11-19 (+1.29%) · Sector: Healthcare
Moderna is a biotech company that develops medicines based on messenger RNA, a molecule that tells the body's cells how to make proteins. It makes money mainly by selling vaccines and by developing treatments, including cancer vaccines, that it partners on or sells to healthcare providers and governments.
Moderna's latest quarter showed revenue of about 1.3 billion dollars and a small profit, a sharp change from the losses in earlier quarters. Over the past year the stock returned 791.5% while the S&P 500 returned 9.7%, so it has beaten the broad market by a wide margin. The stock is still 29.0% below its 52-week high, and company insiders sold about 50.8 million dollars of stock over the last 90 days with no buys. The stock is also far more jumpy than the market, so price swings can be large.
Key numbers
- Market cap: $85.7B
- Revenue (last 12 months): $2.52B
- Revenue growth: +12.5%
- Gross margin: -0.1%
- Operating margin: -116.3%
- P/S: 34.0
- Debt to equity: 0.09
- Current ratio: 3.62
Quality score
Overall 42/100 · growth 40 · profitability 0 · financial health 85 · value None
Performance and risk
1-year return +791.5% vs S&P 500 +9.7% · volatility 194.9% (S&P 500 13.8%) · largest drop -34.2% · beta 2.29
Stock move the day after earnings
- 2026-01-12: -1.3%
- 2026-02-13: +5.3%
- 2026-05-01: -1.2%
- 2026-07-31: -5.4%
- 2026-11-06: +5.3%
Congress trades (90 days)
2 buys, 0 sells
Insider trades (12 months)
Bought $0.0M · sold $98.5M
MRNA stock research · MRNA options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.